Meningococcal Disease

Community Vaccination Can Be Cost Effective

Published in TB and Outbreaks Week, July 10th, 2001

by N.R. Saltmarsh, staff medical writer - Polysaccharide vaccination against serogroup C Neisseria meningitidis may be cost effective under certain conditions, but public health policy makers should consider more than cost when deciding who gets the vaccine.

That is the opinion of S. Skull and colleagues at the Royal Melbourne Hospital, who urged Australian authorities to consider noneconomic factors when deciding whether to implement large-scale meningococcal vaccination programs.

"Disease due to serogroup C N. meningitidis is life-threatening and potentially preventable by vaccination," they pointed out. "In 1999, the U.K. instigated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry